跳到正文

法规知识库 · EMA 集中审评

Privigen

human normal immunoglobulin (IVIg) · EMEA/H/C/000831 · 已授权

获批上市许可

2008-04-24

欧委会决定日

2026-05-26

持有人 / 申请人

CSL Behring GmbH

终止日期字段

无

从产品到官方文件

文件记录

13

官方索引 13

EPAR / 审评

11

assessment / overview 等

产品信息

2

PI / presentations

其他

0

RMP / PIP 等

ATC:J06BA02

治疗领域:Purpura, Thrombocytopenic, Idiopathic;Bone Marrow Transplantation;Immunologic Deficiency Syndromes;Guillain-Barre Syndrome;Mucocutaneous Lymph Node Syndrome

药理分类:Immune sera and immunoglobulins

修订号:34 · 最新影响 PI 的程序:VR/0000304719

适应症(原文):Replacement therapy in adults, and children and adolescents (0-18 years) in: primary immunodeficiency (PID) syndromes with impaired antibody production; hypogammaglobulinaemia and recurrent bacterial infections in patients with chronic lymphocytic leukaemia, in whom prophylactic antibiotics have failed; hypogammaglobulinaemia and recurrent bacterial infections in plateau-phase-multiple-myeloma patients who have failed to respond to pneumococcal immunisation; hypogammaglobulinaemia in patients after allogeneic haematopoietic-stem-cell transplantation (HSCT); congenital AIDS with recurrent bacterial infections. Immunomodulation in adults, and children and adolescents (0-18 years) in: primary immune thrombocytopenia (ITP), in patients at high risk of bleeding or prior to surgery to correct the platelet count; Guillain-Barré syndrome; Kawasaki disease; chronic inflammatory demyelinating polyneuropathy (CIDP). Only limited experience is available of use of intravenous immunoglobulins in children with CIDP.

关键日期时间轴

来自 EMA medicines JSON 日期字段;缺失字段不展示,不补推结论。

  1. 2026-05-26 · 欧委会决定

  2. 2008-04-24 · 获批上市许可

  3. 2008-02-21 · CHMP 意见通过

说明书、EPAR 与其他文件

仅展示 EMA 官方 document_url;本站不下载或镜像 PDF。

EPAR / 审评资料 11产品信息 2其他 0

EPAR / 审评资料

  • Privigen- PAM-0000319183 : EPAR - Assessment Report

    variation-report · 2026-07-31 · EMADOC-1700519818-3181751

    打开官方文件 ↗
  • Privigen : EPAR - Procedural steps taken and scientific information after authorisation

    procedural-steps-after · 2026-06-24

    打开官方文件 ↗
  • Privigen-VR-0000304719 : EPAR - Assessment report - Variation

    variation-report · 2026-06-24 · EMADOC-1700519818-3007695

    打开官方文件 ↗
  • Privigen : EPAR - Risk management plan

    rmp · 2026-06-24

    打开官方文件 ↗
  • Privigen : EPAR - Procedural steps taken and scientific information after authorisation (archive)

    procedural-steps-after · 2026-06-24

    打开官方文件 ↗
  • Privigen : EPAR - Medicine overview

    overview · 2026-06-24 · EMA/612651/2020

    打开官方文件 ↗
  • Privigen-H-C-831-P46-0034.1 : EPAR - Assessment Report

    variation-report · 2023-06-15 · EMA/226228/2023

    打开官方文件 ↗
  • Privigen-H-C-831-P46-034 : EPAR - Assessment Report

    variation-report · 2022-06-10 · EMA/578878/2022

    打开官方文件 ↗
  • Privigen-H-C-831-P46-032 : EPAR - Assessment Report

    variation-report · 2022-03-09 · EMA/CHMP/185004/2019

    打开官方文件 ↗
  • Privigen-H-C-831-II-0063 : EPAR - Assessment Report - Variation

    variation-report · 2013-05-06 · EMA/CHMP/749630/2012

    打开官方文件 ↗
  • Privigen : EPAR - Public assessment report

    assessment-report · 2008-05-20

    打开官方文件 ↗

产品信息

数据来自 EMA 官方 JSON;最终以 EMA / 欧委会文件为准。本页不自动给出安全或非安全结论。